OverviewSuggest Edit

Alligator Bioscience develops antibody-based pharmaceuticals for cancer treatment. The Company is specialized in the development of tumor-targeted immunotherapies, particularly agonistic mono- and bispecific antibodies, and is engaged in the early stages of drug development, from the idea stage to clinical phase II trials.

TypePublic
Founded2001
HQLund, SE
Websitealligatorbioscience.se

Latest Updates

Employees (est.) (Jul 2021)44(+3%)
Share Price (Sept 2021)KR4.6(-1%)
Cybersecurity ratingAMore

Key People/Management at Alligator Bioscience

Marie Svensson

Marie Svensson

CFO
Peter Ellmark

Peter Ellmark

CSO
Anders Ekblom

Anders Ekblom

Director
Graham Dixon

Graham Dixon

Director
Christina Furebring

Christina Furebring

SVP Projects
Laura von Schantz

Laura von Schantz

Director
Show more

Alligator Bioscience Office Locations

Alligator Bioscience has an office in Lund
Lund, SE (HQ)
Scheelevägen 12
Show all (1)

Alligator Bioscience Financials and Metrics

Alligator Bioscience Revenue

Market capitalization (3-Sept-2021)

396.2m

Closing stock price (3-Sept-2021)

4.6
Alligator Bioscience's current market capitalization is kr396.2 m.
Show all financial metrics

Alligator Bioscience Cybersecurity Score

Cybersecurity ratingPremium dataset

A

90/100

SecurityScorecard logo

Alligator Bioscience Online and Social Media Presence

Embed Graph

Alligator Bioscience News and Updates

Positive Results from the Scandion Oncology and Alligator Bioscience Collaboration Further Supports Efficacy of Mitazalimab in Combination Therapy

STOCKHOLM, Sept. 2, 2021 /PRNewswire/ -- Alligator Bioscience AB (Nasdaq Stockholm: ATORX) and Scandion Oncology A/S (Nasdaq Stockholm: SCOL), today announced the conclusion of their collaboration with a very positive outcome. The purpose of the collaboration was to explore the anti-tumor...

Alligator Bioscience announces Immuno-oncology Research Collaboration and License Agreement with Orion Corporation

STOCKHOLM, Aug. 18, 2021 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today that the company has entered into a research collaboration and license agreement with Orion Corporation, a global pharmaceutical company based in Finland, to discover and develop...

Orion Corporation and Alligator Bioscience announce immuno-oncology research collaboration and license agreement

ORION CORPORATION PRESS RELEASE 18 AUGUST 2021 at 9.00 a.m. EEST

Alligator Bioscience AB: Interim report January-June 2021

STOCKHOLM, July 13, 2021 /PRNewswire/ -- Positive Phase I data for ATOR-1017 "As new CEO of Alligator Bioscience, after just around a month, let me say that my high expectations on the company have been surpassed already. During this short time, I have been ascertained that Alligator has...

Alligator Bioscience presents positive Phase I data at ASCO for its 4-1BB agonist drug candidate ATOR-1017

LUND, Sweden, June 4, 2021 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) today presents novel supportive data from the ongoing Phase I clinical trial with the 4-1BB (CD137) drug candidate ATOR-1017 developed as tumor-directed therapy for metastatic cancer. The results,...

Alligator Bioscience and BioArctic enter into research agreement in the neurodegenerative field

LUND, Sweden, May 4, 2021 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that it has entered into a joint research agreement with BioArctic AB, a Swedish research-based biopharma company focusing on disease-modifying treatments and reliable biomarkers and...
Show more

Alligator Bioscience Blogs

Alligator Bioscience submits clinical trial application for ATOR-1017

Lund, Sweden, June 18, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, today announced that the company has submitted clinical trial authorization (CTA) application to initiate a Phase I study …

Alligator Bioscience to present the ATOR-1015 Phase I study outline at ASCO

Lund, Sweden, May 16, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that the outline of the ongoing Phase I study with the bispecific drug candidate ATOR-1015 will be showcased at the American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago on May 31- June…

Alligator Bioscience: ADC-1013 clinical Phase I data to be presented at ASCO

Lund, Sweden, May 15, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that Janssen Biotech, Inc. (Janssen) will present data from a Phase I clinical study of ADC-1013 (JNJ-7107) at the upcoming ASCO Annual meeting held in Chicago on May 31- June 4. The study results show that …

Bulletin from the Annual Shareholders’ Meeting in Alligator Bioscience AB (publ) on May 9, 2019

Lund, Sweden, May 9, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, today held an annual shareholders’ meeting. A summary of the resolutions adopted follows below. All resolutions were adopted…

The Nomination Committee’s proposal for the annual shareholders’ meeting in Alligator Bioscience AB (publ)

Lund, Sweden, April 17, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that the Nomination Committee in Alligator Bioscience has presented its proposal for the annual shareholders’ meeting on May 9, 2019, regarding election and remuneration of the board. The Nomination Commit…

Alligator Bioscience: Preclinical data on the tumor-localizing anti-CTLA-4 antibody ATOR-1015 published in the Journal for ImmunoTherapy of Cancer

Lund, Sweden, April 11, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that preclinical data on the CTLA-4 x OX40 bispecific antibody ATOR-1015 is published in the Journal for ImmunoTherapy of Cancer. The published data show that ATOR-1015 localizes to the tumor with anti-tum…
Show more

Alligator Bioscience Frequently Asked Questions

  • When was Alligator Bioscience founded?

    Alligator Bioscience was founded in 2001.

  • Who are Alligator Bioscience key executives?

    Alligator Bioscience's key executives are Marie Svensson, Peter Ellmark and Anders Ekblom.

  • How many employees does Alligator Bioscience have?

    Alligator Bioscience has 44 employees.

  • Who are Alligator Bioscience competitors?

    Competitors of Alligator Bioscience include Kiromic Biopharma, Omnitura Therapeutics and Iterion Therapeutics.

  • Where is Alligator Bioscience headquarters?

    Alligator Bioscience headquarters is located at Scheelevägen 12, Lund.

  • Where are Alligator Bioscience offices?

    Alligator Bioscience has an office in Lund.

  • How many offices does Alligator Bioscience have?

    Alligator Bioscience has 1 office.